Anebulo Pharmaceuticals (214) AI Stock Analysis

Anebulo Pharmaceuticals

(Dusseldorf:214)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Zero debt and positive equityZero interest-bearing debt and positive shareholder equity (~$7.9M) materially reduce refinancing and interest-rate risk. For a clinical-stage biotech this durable balance-sheet position preserves financial flexibility, extending runway and giving management time to reach clinical milestones before forced restructuring.

Negative Factors

Pre-revenue with persistent net lossesAnebulo remains pre-revenue with TTM net losses near -$8.0M, which limits visibility into future margins and commercial viability. This structural profile forces ongoing reliance on external capital, increases dilution risk, and means value realization depends heavily on successful clinical/regulatory milestones rather than operating cash flow.

Anebulo Pharmaceuticals (214) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 9.87M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -1.6
Beta (1Y): -2.47
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 3
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Anebulo Pharmaceuticals Business Overview & Revenue Model

Company Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s le...

Anebulo Pharmaceuticals Risk Analysis

Anebulo Pharmaceuticals disclosed 49 risk factors in its most recent earnings report. Anebulo Pharmaceuticals reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks

1.Inadequate funding for the FDA, the SEC and other government agencies, including from government shutdowns, or other disruptions to these agencies' staffing and operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.Q4, 2025

2.A shutdown of the U.S. federal government may adversely affect our business.Q4, 2025

Anebulo Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:214 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHIO	44Neutral	$9.99M	-0.64	-87.41%	―	―	59.81%
PTN	44Neutral	$8.90M	-0.95	-115.00%	―	―	―
CTXR	43Neutral	$14.36M	-0.25	-67.15%	―	―	57.48%
KALA	43Neutral	$3.20M	-0.00	-222.32%	―	―	78.25%
TPST	42Neutral	$9.91M	-0.11	-1270.11%	―	―	69.34%

* Healthcare Sector Average

Performance Comparison

DE:214 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:214	Anebulo Pharmaceuticals, Inc.	0.43	-1.73	-79.91%
PTN	Palatin Technologies, Inc.	5.00	-1.50	-23.08%
TPST	Tempest Therapeutics, Inc.	0.49	-9.53	-95.06%
PHIO	Phio Pharmaceuticals	0.86	-1.00	-53.76%
KALA	Kala Bio, Inc.	0.17	-37.92	-99.57%
CTXR	Citius Pharma	0.52	-1.00	-65.59%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Anebulo Pharmaceuticals AI Stock Analysis